Customer Success Story: Novo Nordisk + Celonis

Each month, we’re highlighting how our customers are using Celonis to solve complex problems and create real value.

We’re keeping the momentum going with Novo Nordisk.

They’ve been fighting chronic diseases for over 100 years. But in an industry where drug development is notoriously slow Novo Nordisk decided to challenge the status quo.

Their goal? Use Process Intelligence to radically speed up how they bring life-saving treatments to patients.

With trials running across thousands of global sites and bound by complex regulations, getting an end-to-end view of operations was nearly impossible.

By using Celonis to create a "digital twin" of their clinical trials, they built the ultimate foundation for Enterprise AI. Today, they are orchestrating a fleet of over 100 AI agents to safely automate heavily regulated workflows, helping them:

📉 Cut time-to-market by potentially 12 months or more

 ⚙️ Resolve bottlenecks faster across complex drug development flows 

🛡️ Reduce compliance risk by driving consistency across global trials 

🔬 Refocus experts on optimizing therapies instead of chasing data

“Without Process Intelligence, Enterprise AI at scale is hopeful thinking... If you don't have a digital twin of your operation, it's almost impossible to understand where to deploy AI.” – Stephanie Bova, Corporate VP & Digital Transformation Officer, R&D, Novo Nordisk

And the impact is massive, saving a year in development preserves valuable time-on-patent, unlocking tens of millions in peak revenue to fund the next generation of medical breakthroughs.

👉 Read the full story

What do you think? Let us know how you're using Celonis, or where you’re hoping to go next.